Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Xencor, Gilead enter license agreement for use of Xtend, Cytotoxic XmAb Fc » 08:06
01/08/20
01/08
08:06
01/08/20
08:06
XNCR

Xencor

$35.69 /

-0.07 (-0.20%)

, GILD

Gilead

$65.12 /

-0.53 (-0.81%)

Xencor (XNCR) announced…

Xencor (XNCR) announced it has entered into a technology license agreement in which Gilead Sciences (GILD) will access Xencor's Xtend extended half-life and Cytotoxic XmAb Fc technologies for developing and commercializing GS-9722, Gilead's first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development. Under the terms of the agreement, Xencor has granted Gilead an exclusive license for GS-9722 and up to three additional anti-HIV antibodies. Xencor retains the right to grant licenses for other antibodies directed to the target. Gilead will be solely responsible for the activities and costs related to research, development, regulatory and commercial activities. Xencor will receive an upfront payment and is eligible to receive milestones and royalties for the successful development and commercialization of these products.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
Xencor appoints Dr. Allen Yang as Chief Medical Officer » 08:05
12/18/19
12/18
08:05
12/18/19
08:05
XNCR

Xencor

$37.64 /

+0.05 (+0.13%)

, JAZZ

Jazz Pharmaceuticals

$149.13 /

+0.5 (+0.34%)

Xencor (XNCR) announced…

Xencor (XNCR) announced the appointment of Allen Yang, M.D., Ph.D., as senior vice president and Chief Medical Officer. He will be responsible for leading clinical development strategy and overseeing clinical operations for Xencor's portfolio of XmAb antibody drug candidates, including bispecific antibodies and cytokines. Dr. Yang joins Xencor from Jazz Pharmaceuticals (JAZZ), where he served as senior vice president, head of clinical development and acting chief medical officer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Xencor to host analyst & investor meeting » 19:25
12/09/19
12/09
19:25
12/09/19
19:25
XNCR

Xencor

$41.41 /

+0.39 (+0.95%)

Analyst & Investor…

Analyst & Investor meeting to be held in Orlando, FL on December 9 at 8 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Xencor's XmAb13676 showing improving response rates, says Mizuho » 11:24
12/09/19
12/09
11:24
12/09/19
11:24
XNCR

Xencor

$41.76 /

+0.74 (+1.80%)

Xencor's poster…

Xencor's poster presentation with updated data for XmAb13676 shows improving response rates with increasing dose escalation and a manageable safety profile, Mizuho analyst Mara Goldstein tells investors in a research note. The analyst believes a profile of XmAb13676 is emerging with efficacy and safety largely consistent with other bispecifics in the space. Citing "improving clarity" on a path forward, Goldstein maintains a Buy rating on Xencor shares with a $52 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Xencor presents Initial Data from Phase 1 Study of XmAb 13676 » 10:08
12/09/19
12/09
10:08
12/09/19
10:08
XNCR

Xencor

$41.27 /

+0.25 (+0.61%)

Xencor announced initial…

Xencor announced initial data from its ongoing Phase 1 dose-escalation study of XmAb 13676, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies. Data are being presented by Krish Patel, Director of the Lymphoma Program at Swedish Cancer Institute, in a poster session today from 6:00 p.m. to 8:00 p.m. EST at the 61st American Society of Hematology Annual Meeting. At data cut off in November 2019, 45 patients with relapsed/refractory non-Hodgkin's lymphoma (r/r NHL) had received doses of XmAb13676 ranging from 0.7 to 170 mcg/kg, and 8 patients with relapsed/refractory chronic lymphocytic leukemia had received doses ranging from 0.7 to 20 mcg/kg. The study was designed in two parts: Part A to establish an initial priming dose with flat dosing regimens and Part B to escalate dosing on subsequent administrations to the priming dose. Prophylactic treatment for cytokine release syndrome was mandated prior to each dose of XmAb13676. "XmAb13676 has been generally well tolerated and has demonstrated encouraging clinical activity in patients with advanced non-Hodgkin's lymphoma as a monotherapy in initial dose escalation cohorts. This activity supports the potential of XmAb13676 in lymphoma treatment, and we are planning additional studies as a monotherapy and in combination with other agents. Dose escalation and optimization of dosing schedule, using a priming dose and step-up regimen, are ongoing," said Bassil Dahiyat, president and CEO at Xencor.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Xencor to host analyst & investor meeting » 07:29
12/06/19
12/06
07:29
12/06/19
07:29
XNCR

Xencor

$40.63 /

+0.05 (+0.12%)

Analyst & Investor…

Analyst & Investor meeting to be held in Orlando, FL on December 9 at 8 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Jaffray to hold a conference » 08:20
12/03/19
12/03
08:20
12/03/19
08:20
AERI

Aerie Pharmaceuticals

$18.88 /

-0.04 (-0.21%)

, JAZZ

Jazz Pharmaceuticals

$150.31 /

-0.88 (-0.58%)

, REGN

Regeneron

$366.08 /

-3.12 (-0.85%)

, XNCR

Xencor

$38.17 /

-1.22 (-3.10%)

, DTIL

Precision BioSciences

$16.93 /

-0.89 (-4.99%)

, AKBA

Akebia

$5.31 /

-0.97 (-15.45%)

, CHMA

Chiasma

$5.23 /

-0.11 (-2.06%)

, GRTS

Gritstone Oncology

$8.60 /

-0.26 (-2.93%)

, MNK

Mallinckrodt

$3.77 /

+ (+0.00%)

, HCM

Hutchison China MediTech

$24.22 /

+0.13 (+0.54%)

, KRYS

Krystal Biotech

$61.33 /

+5 (+8.88%)

, PCRX

Pacira

$46.12 /

-0.12 (-0.26%)

, EXEL

Exelixis

$16.71 /

+0.07 (+0.42%)

, BOLD

Audentes Therapeutics

$28.59 /

-0.41 (-1.41%)

, AMRX

Amneal Pharmaceuticals

$3.83 /

+0.05 (+1.32%)

, EBS

Emergent BioSolutions

$53.59 /

-1.32 (-2.40%)

, CRIS

Curis

$1.63 /

-0.155 (-8.68%)

, ATNX

Athenex

$15.69 /

+0.12 (+0.77%)

, BBIO

BridgeBio

$31.31 /

+2.25 (+7.74%)

, IMGN

ImmunoGen

$3.56 /

-0.04 (-1.11%)

, RMTI

Rockwell Medical

$2.19 /

-0.08 (-3.52%)

, IOVA

Iovance Biotherapeutics

$22.64 /

-0.16 (-0.70%)

31st Annual Healthcare…

31st Annual Healthcare Conference will be held in New York on December 3-5 with webcasted company presentations to begin on December 3 at 8 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Xencor assumed with a Neutral at Guggenheim » 07:27
11/20/19
11/20
07:27
11/20/19
07:27
XNCR

Xencor

$37.65 /

+1.36 (+3.75%)

Guggenheim analyst Etzer…

Guggenheim analyst Etzer Darout assumed coverage of Xencor with a Neutral rating and no price target. While the analyst sees long-term value in the company's "R&D engine" and its bispecific platform, he believes most of the more near-term pipeline upside drivers are priced into the stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Xencor price target lowered to $44 from $52 at SVB Leerink » 08:07
11/06/19
11/06
08:07
11/06/19
08:07
XNCR

Xencor

$32.99 /

-0.65 (-1.93%)

SVB Leerink analyst…

SVB Leerink analyst Jonathan Chang lowered his price target for Xencor to $44 from $52 after the company reported Q3 results and provided a pipeline update that was in line with expectations. The analyst tells investors in a research note that he continues to view Xencor as a leader in the bispecific space and view the company's "plug-and-play" antibody platform as an important long-term value driver and a potential source of business development opportunities in the future and views Xencor as well-positioned to execute on its long-term strategy with a strong management team and financial position. He keeps an Outperform rating on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Xencor price target lowered to $46 from $67 at Piper Jaffray » 20:47
11/05/19
11/05
20:47
11/05/19
20:47
XNCR

Xencor

$32.99 /

-0.65 (-1.93%)

Piper Jaffray analyst…

Piper Jaffray analyst Edward Tenthoff lowered his price target on Xencor to $46 after its Q3 results and also to reflect his reduced estimated value for XmAb5871 and XmAb7195 programs. The analyst notes that the company does not plan to advance its obexelimab, or XmAb5871, program in either IgG4-Related Disease or lupus without a partner, adding that the same applies to XmAb7195 in asthma. The analyst still keeps his Overweight rating on the stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.